This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?
by Ahan Chakraborty
LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.
LLYPositive Net Change AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
by Ekta Bagri
Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.
BMYNegative Net Change GERNPositive Net Change KROSPositive Net Change
biotechs pharmaceuticals
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
by Zacks Equity Research
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
BBIOPositive Net Change BMRNNegative Net Change ASNDPositive Net Change
biotechs medical
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
by Debanjana Dey
ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.
ELTPNegative Net Change AYTUNegative Net Change
biotechnology biotechs medical pharmaceuticals
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX
by Zacks Equity Research
Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
HALOPositive Net Change JNJPositive Net Change ARGXPositive Net Change HOWLPositive Net Change
biotechs
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
by Ahan Chakraborty
Novo's semaglutide expansion into liver disease and other obesity-related conditions can unlock growth, but competition and clinical risks loom.
NVOPositive Net Change LLYPositive Net Change ALTPositive Net Change MDGLNegative Net Change
biotechnology biotechs medical pharmaceuticals
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
by Zacks Equity Research
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
INSMPositive Net Change VKTXPositive Net Change ACIUNegative Net Change
biotechs medical
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
by Zacks Equity Research
Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.
PCRXNegative Net Change ALNYPositive Net Change ALDXNegative Net Change ACIUNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Down 16% in a Month: Time to Invest or Exit the Stock?
by Sundeep Ganoria
Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.
VKTXPositive Net Change NVOPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
by Zacks Equity Research
NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.
NVSPositive Net Change IONSPositive Net Change ACIUNegative Net Change PGENPositive Net Change
biotechnology biotechs medical pharmaceuticals